Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management By: Newsfile November 30, 2023 at 09:45 AM EST Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and its impact on patients, particularly those suffering from Primary Biliary Cholangitis (PBC), an autoimmune liver disease. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Stonegate Healthcare Partners identifies leading programs aiming to reshape the landscape of pruritus treatment and significantly improve patients' quality of life. Companies featured in the report include ConnectBiopharma (NASDAQ: CNTB), Ironwood Pharmaceuticals (NASDAQ: IRWD), MirumPharmaceuticals (NASDAQ: MIRM), and Tharimmune (NASDAQ: THAR). Click image above to view full announcement. About Stonegate Healthcare Partners Our mission at Stonegate Healthcare Partners is to accelerate meaningful innovations in healthcare through Strategy, Market Intelligence, Business Development, and Investor Outreach. The firm's research approach is centered on comprehensive and comparative analyses in specific healthcare fields. We strive to pinpoint programs that align closely with our strategic vision for the space and focus on technologies with the greatest potential for disruption. Stonegate Healthcare builds on its foundational thematic research by continuously gathering market intelligence, further enabling a current understanding of unmet needs and emerging disruptive technologies. Contact:Alamgir Kandhari alamgir@stonegateinc.com Source: Stonegate Healthcare To view the source version of this press release, please visit https://www.newsfilecorp.com/release/189274 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management By: Newsfile November 30, 2023 at 09:45 AM EST Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and its impact on patients, particularly those suffering from Primary Biliary Cholangitis (PBC), an autoimmune liver disease. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Stonegate Healthcare Partners identifies leading programs aiming to reshape the landscape of pruritus treatment and significantly improve patients' quality of life. Companies featured in the report include ConnectBiopharma (NASDAQ: CNTB), Ironwood Pharmaceuticals (NASDAQ: IRWD), MirumPharmaceuticals (NASDAQ: MIRM), and Tharimmune (NASDAQ: THAR). Click image above to view full announcement. About Stonegate Healthcare Partners Our mission at Stonegate Healthcare Partners is to accelerate meaningful innovations in healthcare through Strategy, Market Intelligence, Business Development, and Investor Outreach. The firm's research approach is centered on comprehensive and comparative analyses in specific healthcare fields. We strive to pinpoint programs that align closely with our strategic vision for the space and focus on technologies with the greatest potential for disruption. Stonegate Healthcare builds on its foundational thematic research by continuously gathering market intelligence, further enabling a current understanding of unmet needs and emerging disruptive technologies. Contact:Alamgir Kandhari alamgir@stonegateinc.com Source: Stonegate Healthcare To view the source version of this press release, please visit https://www.newsfilecorp.com/release/189274
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and its impact on patients, particularly those suffering from Primary Biliary Cholangitis (PBC), an autoimmune liver disease. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Stonegate Healthcare Partners identifies leading programs aiming to reshape the landscape of pruritus treatment and significantly improve patients' quality of life. Companies featured in the report include ConnectBiopharma (NASDAQ: CNTB), Ironwood Pharmaceuticals (NASDAQ: IRWD), MirumPharmaceuticals (NASDAQ: MIRM), and Tharimmune (NASDAQ: THAR). Click image above to view full announcement. About Stonegate Healthcare Partners Our mission at Stonegate Healthcare Partners is to accelerate meaningful innovations in healthcare through Strategy, Market Intelligence, Business Development, and Investor Outreach. The firm's research approach is centered on comprehensive and comparative analyses in specific healthcare fields. We strive to pinpoint programs that align closely with our strategic vision for the space and focus on technologies with the greatest potential for disruption. Stonegate Healthcare builds on its foundational thematic research by continuously gathering market intelligence, further enabling a current understanding of unmet needs and emerging disruptive technologies. Contact:Alamgir Kandhari alamgir@stonegateinc.com Source: Stonegate Healthcare To view the source version of this press release, please visit https://www.newsfilecorp.com/release/189274